### Analysis:
Merck & Co., Inc. reported strong earnings for the second quarter of 2007, with EPS of $0.82 excluding restructuring charges, a 12% increase from the same period last year. The company also reported $6.1 billion in sales, a 6% increase from the same period last year. Merck's strong performance was driven by a broad range of both its newer and established products, with SINGULAIR, VYTORIN, ZETIA, and GARDASIL all showing significant growth. The company also reported strong sales for JANUVIA and JANUMET, and its vaccine business continued to perform well. Merck's guidance for the full year 2007 was also raised, with the company now expecting EPS of $3 to $3.10, excluding restructuring charges, and reported EPS of $2.80 to $2.95. The company also expects its product gross margin to be approximately 75% to 76% for the year. Merck's management also discussed the company's ongoing efforts to control expenses and create a leaner and more nimble business model. The company also discussed its strategic growth initiatives, including its ongoing licensing and acquisition efforts, and its commitment to discovering, developing, and marketing novel medicines that address unmet medical needs.

### Conclusion:
Merck & Co., Inc.'s strong earnings report and guidance raise for the full year 2007 are likely to have a positive impact on the stock price in the short term (1â€“2 weeks). The company's strong performance and guidance indicate that it is on track to meet its long-term goals and continue to deliver value to shareholders. Additionally, the company's ongoing efforts to control expenses and create a leaner and more nimble business model, as well as its strategic growth initiatives, suggest that the company is well-positioned to continue to grow and deliver strong results in the future. Therefore, the stock is likely to see a positive impact in the short term.

### Rating:
1